Results 161 to 170 of about 6,391 (198)

Late Mortality Among Survivors of Childhood Cancer in Canada: A Retrospective Cohort Study

Pediatric Blood &Cancer, Volume 72, Issue 7, July 2025.
ABSTRACT Background Children with cancer face an increased risk of complications and death beyond the 5‐year survival mark. National surveillance efforts facilitate the systematic tracking of long‐term health outcomes, including treatment‐related complications and late mortality, among childhood cancer survivors.
Katherine McKenzie, Brianna Belanger, Shruti Parshad, Lin Xie, Vera Grywacheski, Miranda Fidler‐Benaoudia   +5 more
wiley   +1 more source

Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study

Pediatric Blood &Cancer, Volume 72, Issue 7, July 2025.
ABSTRACT Background Metabolic syndrome (MetS), a risk factor for early cardiovascular morbidity and mortality, is seen in up to 34% of survivors of childhood acute lymphoblastic leukemia (ALL). Procedure We performed a Danish, national cross‐sectional study of ALL survivors (aged 1–45 years at diagnosis) treated according to the NOPHO ALL2008 protocol,
Mette Tiedemann Skipper, Niels Birkebæk, Rikke Beck Jensen, Bente Lomholt Langdahl, Ruta Tuckuviene, Peder Skov Wehner, Kjeld Schmiegelow, Thomas Leth Frandsen, Liv Andrés‐Jensen, Birgitte Klug Albertsen   +9 more
wiley   +1 more source

Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia

Pediatric Blood &Cancer, Volume 72, Issue 7, July 2025.
ABSTRACT Background Venetoclax is a potent, oral BCL‐2 inhibitor approved as combination therapy for the treatment of adults with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. This study evaluated the safety and preliminary efficacy of venetoclax alone or combined with chemotherapy in paediatric and ...
Seth E. Karol, Seong L. Khaw, C. Michel Zwaan, Andre Baruchel, Henrique Bittencourt, Todd M. Cooper, Christian Flotho, Christopher Fraser, Christopher J. Forlenza, Kelly C. Goldsmith, Margaret E. Macy, Daniel A. Morgenstern, Maureen M. O'Brien, Arnaud Petit, David S. Ziegler, Dirk Reinhardt, Joseph T. Opferman, Jeffrey E. Rubnitz, Maika Onishi, Diana R. Dunshee, Fengjiao Dunbar, Deeksha Vishwamitra, Jeremy A. Ross, Xin Chen, Kristina Unnebrink, Maja Kammerlander, Ahmed Hamed Salem, Tammy L. Palenski, Gauri Sunkersett, Andrew E. Place   +29 more
wiley   +1 more source

What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies

Pediatric Blood &Cancer, Volume 72, Issue 7, July 2025.
ABSTRACT High‐dose methotrexate dosage and infusion durations differ across treatment protocols for pediatric leukemia, lymphoma, and osteosarcoma. Supportive care interventions are dependent on a patient's elimination of methotrexate (MTX). Therefore, it is important to establish the expected MTX elimination across protocols.
Zachary L. Taylor, Tamara P. Miller, Sarah G. Board, Ethan A. Poweleit, Ashley Chavana, Allison Weisnicht, Austin L. Brown, Melanie B. Bernhardt, Eric S. Schafer, Maureen M. O'Brien, Sharon M. Castellino, Laura B. Ramsey   +11 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Acute Lymphoblastic Leukemia

Hematology, 2002
AbstractThis is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic leukemia (ALL).Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches, prognostic factors, risk stratification, and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies ...
Dieter, Hoelzer, Nicola, Gökbuget, Oliver, Ottmann, Ching-Hon, Pui, Mary V, Relling, Frederick R, Appelbaum, Jacques J M, van Dongen, Tomasz, Szczepański   +7 more
openaire   +4 more sources

Acute Lymphoblastic Leukemia

Clinics in Laboratory Medicine, 2000
Over the last two decades, great strides have been made in the treatment of acute lymphoblastic leukemia (ALL). This progress has been paralleled by advances in diagnosis. In addition to morphology and cytochemistry, the diagnostic and prognostic importance of immunophenotypic and genetic features is becoming increasingly apparent. This article reviews
D C, Farhi, N S, Rosenthal
openaire   +2 more sources

Acute Lymphoblastic Leukemia

2007
Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of disorders which originate from various important genetic lesions in B and T progenitor cells, including mutations that lead to stage-specific developmental arrest and those that impart the capacity for unlimited self-renewal, resulting in clonal expansion of immature progenitor cells
Biondi A., Scrideli C. A., Cazzaniga G.
openaire   +2 more sources

Acute Lymphoblastic Leukemia

Pediatric Clinics of North America, 1997
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire   +3 more sources

Acute Lymphoblastic Leukemia

Clinics in Laboratory Medicine, 1999
This article reviews the laboratory methodologies used to evaluate acute lymphoblastic leukemia (ALL) in children and their role in establishing a diagnosis and prognosis of this disease. These methodologies are: morphology, flow cytometry, cytogenetics, and molecular diagnostics.
openaire   +2 more sources

Granular Acute Lymphoblastic Leukemia

American Journal of Clinical Pathology, 1983
Granules in blasts are most typical of acute myeloblastic leukemia. However, there have been scattered reports of patients with acute lymphoblastic leukemia (ALL) that have lymphoblasts with azurophilic cytoplasmic granules. These reports do not describe immunologic markers or cytogenetics.
Debra Butler, Dorothy L. Williams, Sanford Stass, S C Peiper, Susan L. Melvin, Preston Stein   +5 more
openaire   +4 more sources